Bio-Rad Laboratories Inc. (BIO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Bio-Rad Laboratories Inc. (BIO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

342.00

-9.70 (-2.76%)

At close: Jan 14, 2025, 3:59 PM

342.95

0.28%

Pre-market Jan 15, 2025, 07:06 AM EST

undefined% (undefined)

Bid	243.96
Market Cap	9.58B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-28.09
PE Ratio (ttm)	-12.18
Forward PE	n/a
Analyst	Buy

Ask	477.29
Volume	168,901
Avg. Volume (20D)	184,375
Open	351.70
Previous Close	351.70
Day's Range	336.67 - 355.05
52-Week Range	262.12 - 387.99
Beta	undefined

About BIO

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, ...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Feb 27, 1980

Employees 7,700

Stock Exchange NYSE

Ticker Symbol BIO

Website https://www.bio-rad.com

Analyst Forecast

According to 4 analyst ratings, the average rating for BIO stock is "Buy." The 12-month stock price forecast is $417.5, which is an increase of 22.08% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Bio-Rad Laboratories Inc. is scheduled to release its earnings on Feb 13, 2025, during market hours.
Analysts project revenue of $682.15M, reflecting a 0.14% YoY growth and earnings per share of 2.88, making a -7.10% decrease YoY.

Why Price Moved

2 months ago · Source

+2.86%

Bio-Rad Laboratories shares are trading higher aft... Unlock content with Pro Subscription

2 months ago · Source

+8.35%

Bio-Rad Laboratories shares are trading higher after the company reported better-than-expected Q3 financial results.

News

1 week ago · businesswire.com

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chie...

2 months ago · zacks.com

Interpreting Bio-Rad (BIO) International Revenue Trends

Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

2 months ago · proactiveinvestors.com

Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collab...

2 months ago · zacks.com

BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.

2 months ago · businesswire.com

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

2 months ago · seekingalpha.com

Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman ...

2 months ago · zacks.com

Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $2.33 per share a year ago.

2 months ago · reuters.com

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

Diagnostics firm Bio-Rad Laboratories posted third-quarter profit above Wall Street estimates on Wednesday, helped by a recovery in demand for analytical tools from its biotech clients and steady clin...

2 months ago · zacks.com

What to Expect From These 3 MedTech Stocks This Earnings Season

Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow.

2 months ago · zacks.com

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

BIO Gears Up for Q3 Earnings: Here's What You Need to Know

Within Bio-Rad's Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely affected sales.